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Abstract
Treatment retention is of paramount importance in cocaine treatment research as treatment
completion rates are often 50% or less. Failure to retain cocaine patients in treatment has both
significant research and clinical implications. In this paper we qualitatively and quantitatively
demonstrate the inconsistency found across analyses of retention predictors in order to highlight the
problem. First, a qualitative review of the published literature was undertaken to identify the
frequency of predictors studied and their relations to treatment retention. Second, an empirical
demonstration of predictor stability was conducted by testing a common set of variables across three
similar 12-week cocaine clinical trials conducted by the same investigators in the same research clinic
within a 5 year period. Results of the literature review indicated inconsistently selected variables of
convenience, widely varying statistical procedures, and discrepant findings of significance. Further,
quantitative analyses resulted in discrepancies in variables identified as significant predictors of
retention among the three studies. Potential sources of heterogeneity affecting the consistency of
findings across studies and recommendations to improve the validity and generalizability of predictor
findings in future studies are proposed.
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1. Introduction
Treatment retention is of paramount importance in addiction studies, and has been stressed as
a primary endpoint, particularly for cocaine treatment (Satel and Kosten, 1991, Montoya et al.,
1995, Lavori et al., 1999). While retention is poor across the majority of substance abuse
treatment studies, treatment completion rates in cocaine clinical trials are often 50% or less
(e.g., Johnson et al, 2006; Levin et al., 2006; Schmitz et al, 2001). Failure to retain patients in
treatment has both significant research and clinical implications. From a research methodology
perspective, retention is necessary to maintain internal validity, as patient dropout may bias
the composition of groups as well as reduce statistical power (Friedman et al., 1998). If dropouts
differ from non-dropouts on characteristics other than completion status, external validity is
also threatened. Treatment effects may not generalize to all treatment-seeking, cocaine
dependent individuals, but rather to the rarefied subset who completed a clinical trial. Reporting
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outcomes on those with less therapeutic exposure, or on only those who completed treatment,
can result in biased estimates of intervention efficacy.
From a clinical perspective, some evidence suggests that participants who leave treatment
programs prematurely fare worse than those who remain for the duration (Bleiberg et al.,
1994, De Leon, 1991). The seminal paper by Baekeland and Lundwall (1975) on treatment
retention in a variety of settings suggested that “dropping out” is a negative treatment indicator.
Within the drug abuse literature, however, the effect of retention may vary by substance. For
example, opiate-dependent patients who remain in treatment are more likely to be drug free
and have lower relapse rates (Stark, 1992). Among cocaine-dependent samples, however, the
relation between time in treatment and outcome has been less consistent (Carroll et al.,
1994). More recent cocaine treatment studies, however, including an investigation of 5-year
outcomes, suggest better outcomes for patients who have more exposure to treatment,
particularly those with a high severity of drug and psychosocial problems (Simpson et al., 1999,
2002).
Because of both methodological and clinical issues, predictors of attrition and retention have
become a major focus of research. Numerous studies in the past 15 years have attempted to
identify key predictors of retention (e.g., Washton, 1990, Kleinman et al., 1992, Agosti et al.,
1996, Alterman et al., 1997, Siqueland et al., 1998, Kampman et al., 2001, Milligan et al.,
2004, Sayre et al., 2002, Means et al., 1989). The authors of this paper have been among the
contributors to this literature (e.g., Sayre et al., 2002). A cursory review of the retention
literature, however, indicates large inconsistencies in methods and findings. For example, some
studies have found demographic characteristics such as age, race, gender, and marital status to
be predictive of retention (e.g., Kleinman et al., 1992, Sayre et al., 2002, Carroll et al., 1994),
while others have not (e.g., Hoffman et al., 1994, Carroll et al., 1991). Drug use severity
variables have also been related to retention in some studies (e.g., Means et al., 1989, Gainey
et al., 1993), but not in others (Kleinman et al., 1992). With notable exceptions (e.g., Joe et al.,
1999), the result of such studies has been a large body of literature seemingly of limited use
with findings of questionable generalizability.
In this paper we qualitatively and quantitatively demonstrate the inconsistency found across
cocaine treatment predictor analyses in order to sufficiently highlight the problem. The focus
will be on cocaine treatment retention due to the especially poor cocaine treatment retention
rates and also to avoid systematic sources of inconsistency (i.e., variations in retention related
to different substances of abuse). Potential sources of heterogeneity affecting the consistency
of findings across studies and recommendations to improve the validity and generalizability
of predictor findings in future studies are proposed. First, a qualitative review of the published
literature was undertaken to identify the frequency of predictors studied and their relations to
treatment retention. Second, we conducted an empirical demonstration of predictor stability
by testing a common set of variables across three similar 12-week cocaine clinical trials
conducted by the same investigators in the same research clinic (Grabowski et al., 2000,
Schmitz et al., 2001). Together, this work identifies a number of problems in predicting cocaine
treatment retention and solutions for improving methodology and potential for generalizability
in this area of research.
2. Methods: Qualitative study
2.1. Study selection
Studies published between January 1980 and August 2004 were considered in the current paper.
Initial identification of studies for the review portion of this paper began with a search of three
widely used computer databases, PsychINFO (American Psychological Association),
MEDLINE (National Library of Medicine), and Web of Science (Thompson Corporation).
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Queries were conducted employing combinations of the word cocaine with the key words
attrition, retention, dropout, prediction, predictors, and correlates. Reference lists provided
in the collected literature were further examined for studies appropriate for the present review
(i.e., “snowballing”). In addition, papers that met inclusion criteria were submitted for cited
reference searches through the Web of Science database to identify publications that
subsequently cited the index publications.
2.2. Study inclusion criteria
Studies included in the present review were those that: (a) involved outpatient treatment
(pharmacological, psychological, or both); (b) involved participants with a primary diagnosis
of cocaine abuse, dependence, or problem cocaine use; (c) evaluated multiple predictors or
correlates of treatment completion or attrition; (d) were written in English or had been translated
into English; and (e) were published in peer-reviewed journals.
2.3. Study exclusion criteria
Conference abstracts were not included in the present review, as they report data of a
preliminary nature and generally offer limited description of research methods. Unpublished
studies and dissertations were also not included, as they have not undergone the rigorous peer-
review process.
2.4. Review variables
In studies meeting inclusion criteria, information concerning study design, analysis techniques,
and predictors of treatment retention were abstracted. Subsequently, evaluative judgements
using standardized coding forms forced predictors into one of seven superordinate (e.g.,
demographics) and 27 subordinate (e.g., gender) categories. The superordinant and subordinate
categories are listed in Table 1. Inter-rater agreement was excellent for both superordinant
categories (Cohen’s κ = 0.91, 95% C.I., 0.86, 0.95), and subordinate categories (Cohen’s κ =
0.80, 95% C.I., 0.73, 0.85), where κ values > .74 are considered in the excellent range
(Cicchetti, 1994).
3. Results: Qualitative Study
A total of 23 studies were identified that met inclusion criteria (see Appendix A). Results of
our literature review indicated marked variability in sample size (Median = 128, Range = 50
– 428), number of predictors (Median = 7, Range = 1 – 45), and observation period (Median
= 74 days, Range = 30 – 360). The majority of reports employed data from prospective
pharmacotherapy or psychotherapy clinical trials (n = 16, 70%), while a minority employed
observational datasets from treatment centers (n = 7, 30%). The types of analyses in order of
most frequent use were: logistic regression (n = 8, 30.4%), ANOVA/ANCOVA (n = 6, 26.1%),
survival analysis (i.e., Cox or Kaplan-Meier regression; n = 5, 21.7%), linear regression (n =
2, 8.7%), and bivariate analysis (i.e., t-tests, zero-order correlations; n = 2, 8.7%).
A total of 201 predictor variables were evaluated across the 23 studies. Due to the heterogenous
nature of the analyses and predictor variables, we chose to summarize our findings in vote-
tally format (Hunter and Schmidt, 1990). However, due to the fallibility of inferences about
significant versus non-significant variables, we do not formally assess predictors for plurality
(Hunter and Schmidt, 1990). The most frequent superordinate categories were found in the
following order: substance abuse (n = 85, 38.3%), demographic (n = 65, 29.3%), psychological
(n = 38, 17.1%), other (n = 13, 5.9%) legal (n = 10, 5.0%), family (n = 6, 2.7%), and
psychotherapy (n = 5, 2.3%). Table 1 reflects the lack of unanimity across studies on the
statistical significance of various predictor variables.
Stotts et al. Page 3
Addict Behav. Author manuscript; available in PMC 2008 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4. Summary: Qualitative Study
A qualitative literature review was performed to determine the consistency of variable selection
and findings in studies designed to identify predictors of retention in treatment for cocaine
abusing or dependent patients. The literature specific to cocaine treatment retention indicated
that: (1) numerous variables have been inconsistently selected and tested; (2) statistical
techniques vary widely; and (3) discrepant findings of significance exist across studies. The
majority of selected variables were arbitrarily chosen post-hoc (e.g., demographic variables),
devoid of theory, and analyzed with test statistics intended for testing pre-specified hypotheses
(Moye, 2000).
5. Method: Quantitative Study
5.1. Participants & Procedures
The selected studies were conducted at the Treatment Research Clinic (TRC), a component of
the Substance Abuse Research Center in the Department of Psychiatry and Behavioral Science
at the University of Texas-Houston Medical School. The clinic itself is described elsewhere
(Grabowski et al., 1997). The data presented in this paper were collected over a five-year period
(1994–1999) as part of three randomized clinical trials for the treatment of cocaine dependence.
All participants were recruited through advertisements in local media sources. Participants took
part in an initial telephone screen to determine initial eligibility for an evaluative appointment.
To be included in the trials, callers had to be: (a) English-speakers; (b) between the ages of 18
and 55; and (c) current users of cocaine. Common exclusion variables included: (a) pregnancy;
(b) current dependence on substances other than cannabis or nicotine; (c) current Axis I
psychotic, affective, or anxiety disorders (DSM-IV, (American Psychiatric Association,
1994); and (d) serious medical conditions.
Eligible callers were invited to participate in a 3–10 day pre-treatment evaluation, which
included a physical exam, lab work, psychiatric assessment, and a series of questionnaires
assessing demographics, substance use, and psychosocial functioning. Upon successful
completion of the pre-treatment evaluation, participants began the 12-week, outpatient
treatment programs which incorporated both therapy and medication components. Each of the
three clinical trials was approved by the University of Texas-Houston Committee for the
Protection of Human Subjects and is described in further detail below.
Activities common to clinic visits across the three studies included: (a) receiving medication,
(b) provision of urine samples at each visit; (c) collection of vital signs; and (d) completion of
self-report questionnaires. Participants were each compensated $10–20 per week during
treatment. Sample sizes vary slightly from the original reports of the following studies due to
missing data on various measures.
Study 1—This study (October 1994–October 1997) was a 12-week trial examining the
effectiveness of three doses of risperidone (2, 4 or 8 mg) compared with placebo in an abuse/
dependent population of 80 cocaine users who entered the treatment phase (Grabowski et al.,
2000). Following stabilization on the medication, participants attended the clinic twice a week
for treatment. All participants attended cognitive behavioral therapy once per week.
Study 2—This study (May 1995–November 1999) was a 12-week relapse prevention trial
examining the effectiveness of naltrexone (50 mg) compared with placebo in a population of
80 cocaine dependent individuals who achieved initial abstinence (5 consecutive days with
cocaine-free urine samples Schmitz et al., 2001). Participants of the program attended the clinic
twice per week during the treatment phase. Cognitive behavioral therapy was provided twice
Stotts et al. Page 4
Addict Behav. Author manuscript; available in PMC 2008 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
per week for the first 8 weeks of treatment and once per week during the final 4 weeks of
treatment.
Study 3—This study (April 1995–August 1998) was a 12-week trial examining the
effectiveness of two doses of dextro-amphetamine sulfate (final dose 30 or 60 mg sustained
release) compared with placebo in an abuse/dependent population of 106 cocaine users entering
the treatment phase (Grabowski et al., 2001). Following stabilization on the medication,
participants attended the clinic twice a week for treatment. During week 5, a dose increase
from 15 mg to 30 mg or from 30 mg to 60 mg occurred. Cognitive behavioral therapy was
provided weekly.
5.2. Measures
Across the three studies, common measures were selected based on the frequency analysis of
variables employed in the literature review and availability. Measures included a demographic
questionnaire, the Addiction Severity Index (ASI, McLellan et al., 1992), the Cocaine Craving
Scale (CCS, Halikas et al., 1991)(measured on a 10 cm visual analogue scale), the University
of Rhoade Island Change Assessment (URICA, McConnaughy et al., 1983), the Beck
Depression Inventory (BDI, Beck et al., 1961), and laboratory measures of benzoylecgonine
(BE: cocaine positive status was defined as a BE value ( 300 ng/mL, Preston et al., 1997).
5.3. Outcomes
Treatment completion was evaluated in two ways to promote comparison with the published
literature. First, treatment completion was defined dichotomously (0 = dropped out before end
of treatment period; 1 = completed treatment). Second, treatment completion was evaluated as
a continuous variable based on the number of days in treatment (1 to 84 days).
5.4 Analysis
All analyses were conducted using the Statistical Analysis System, Version 9.1 (SAS, 2004).
Type-I error rate was controlled on a studywise basis, using Bonferroni adjustments. Three
analytic strategies were implemented based on those most commonly reported in the literature
review: (a) bivariate correlation; (b) logistic regression; and (c) Cox regression (i.e., survival
analysis). In addition, as an extension of current methods, bootstrap resampling methods were
implemented to evaluate the stability of the identified predictors for logistic regression
(Steyerberg et al., 1999, Sauerbrei and Schumacher, 1992, Chen and George, 1985, Austin and
Tu, 2004). The bootstrap is used to assess variability of test statistics, allowing one to estimate
an empirical distribution function by repeated sampling from the observed data. Bootstrap
methods are particularly useful for approximating the distribution of test statistics in small
samples (Austin and Tu, 2004). Regression models were constructed with consideration of
multicollinearity (i.e., redundant measures of drug and alcohol use were excluded) with the
following variables included: (a) medication (covariate; 0 = placebo; 1 = active); (b) age; (c)
education; (d) gender; (e) race (0 = White; 1 = Non-white); (f) marital status (0 = married; 1
= non-married); (g) employment status (0 = unemployed; 1 = employed), (h) number of days
of cocaine use in past 30 days, (i) alcohol use in past 30 days, (j) number of previous drug
treatments, (k) intake urine status (0 = cocaine negative; 1 = cocaine positive [BE value ≥ 300
ng/mL]), (l) craving score, (m) motivation (0 = unmotivated; 1 = motivated) (dichotomized
scoring of the URICA, see Stotts et al., 2001), (n) ASI Family composite, (o) ASI Psychiatric
composite, (p) ASI Legal Composite, and (q) BDI score. Automatic variable selection criteria
were as follows: forward (entry, p ≤ .10; backward, (retention, p ≤ .10), and stepwise (entry,
p ≤ .25, retention, p ≤ .10)(Austin and Tu, 2004).
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6. Results
6.1. Sample Description
The current study samples are presented in Table 2. Across the three studies, most participants
were young, not married, non-white males with at least a high school education. The majority
of participants used cocaine by smoking it, and had used cocaine for nearly a decade. Retention
curves for the three studies are shown in Figure 1.
6.2. Correlates of Retention
Bivariate associations between selected variables are shown in Table 3. Overall, correlation
coefficients were quite low. Following Bonferroni adjustments, no predictors achieved
statistical significance, whether retention was modeled as a continuous outcome (i.e., days of
treatment completed) or dichotomous outcome (i.e., treatment completed or not)
6.3. Regression Analyses
Full-rank regression models were evaluated for each study for both retention outcomes (study
completion, days completed). Although p <.05 was considered the cutoff for significance,
variables achieving p <.10 are also considered.
6.3.1. Logistic regression—In both studies 1 and 2, less cocaine use in the 30 days
preceding entry to the trial predicted retention, χ²(1) = 5.64, p = 0.0175, and χ²(1) = 3.15, p =
0.0761, respectively. In study 3, greater years of education, χ²(1) = 3.91, p = 0.0481, and fewer
days of alcohol use in the 30 days preceding the trial, χ²(1) = 2.72, p = 0.0994, predicted
retention.
6.3.2. Cox regression—No predictor variables were shared in any of three models. In study
1, participants with greater days of cocaine use in the 30 days before treatment, χ²(1) = 7.20,
p = 0.0073, and greater craving for cocaine at the start of treatment, χ²(1) = 3.80, p = 0.0513,
dropped out earlier. In study 2, being older, χ²(1) = 7.62, p = 0.0058, and drinking alcohol more
frequently in the last 30 days, χ²(1) = 3.92, p = 0.0478, was associated with earlier drop out.
In study 3, education level positively predicted longer time in treatment, χ²(1) = 7.61, p =
0.0058, along with fewer days using alcohol in the month preceding treatment, χ²(1) = 3.91,
p = 0.0478, fewer previous drug and alcohol treatments, χ²(1) = 3.32, p = 0.0686, and lower
ASI legal composite scores, χ²(1) = 3.33, p = 0.0679.
6.4. Automatic Variable Selection
In order to illustrate the instability of models constructed through AVS, logistic regression
models were evaluated in two ways. First, we examined the models selected through forward,
backward, and stepwise AVS techniques. Second, we employed bootstrap resampling to
evaluate the stability of model selection using 1,000 samples.
6.4.1. Individual studies—Results of AVS logistic regressions for each study are shown
in Table 4.
In study 1, only greater age and fewer days of cocaine use were consistently predictive of study
completion across the AVS techniques, whereas the ASI family composite (forward AVS) and
sex (backward AVS) were retained with only 1 technique. In study 2, greater years of education
was a stable predictor of study completion. In study 3, only the backward AVS selected a
model, showing greater cocaine use in the 30 days preceding treatment, intake urine sample
positive for cocaine, and fewer psychiatric complaints were predictive of study completion.
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6.4.2. Bootstrap resampling—Results of bootstrap resampling analyses are presented in
Figure 2.
In study 1, the typical model contained about 4 variables (forward, M = 4.3, SD = 1.8; backward,
M = 4.8, SD = 2.6; and stepwise, M = 3.0, SD = 1.4). Inspection of Figure 2 illustrates that only
age and cocaine use in the 30 days preceding treatment were included in more than half of
1000 derived models.
In study 2, the typical model contained about 4 variables (forward, M = 4.3, SD = 1.8; backward,
M = 4.3, SD = 2.0; and stepwise, M = 3.3, SD = 1.6). Few variables were frequently included
with any consistency, and in some cases, inclusion strongly varied by AVS approach (e.g., age,
cocaine use, and education).
In study 3, the typical model contained about 4 variables (forward, M = 3.5, SD = 1.4; backward,
M = 4.1, SD = 1.9; and stepwise, M = 3.3, SD = 1.6). Only cocaine use in the 30 days preceding
treatment and intake urine sample positive for cocaine showed some consistency as predictors
of treatment dropout.
7. Summary: Quantitative Study
Results of quantitative analyses of three cocaine pharmacotherapy treatment studies provide
further evidence suggesting the instability of post-hoc analyses conducted to identify retention
predictors. Despite the fact that the cocaine trials were conducted by the same investigators
within the same research clinic within a 5 year period, almost no overlap existed across studies
in predictor variables found to be associated with cocaine treatment retention. Further, logistic
regression models on the same variables using three automated variable selection methods (i.e.,
forward selection, backward selection, and stepwise selection) within each study produced
varying results. Finally, bivariate correlations between the predictor variables and two separate
measures of retention—one continuous and one dichotomous—indicated a notable absence of
association for all variables, similar to what has been found in past studies (e.g., Kleinman et
al, 1992; Roberts & Nishimoto, 1996). Somewhat surprising is the fact that medication
condition did not predict retention in any of the three studies given the visually-different
retention curves associated with each. Methodological explanations discussed subsequently
may account for the lack of contribution found for medication and perhaps other seemingly
relevant variables.
8. Conclusions
Cumulative results of the qualitative and quantitative studies highlight significant
inconsistencies that cast doubt on the meaningfulness or generalizability of the current
literature on cocaine treatment retention. Generalizability can be defined as the ability of a
“system” or model to provide accurate predictions in a different sample of patients. Justice et
al. (1999) state that, “…a system that can only predict outcomes in the sample in which it was
developed is useless.” Thus, in the cocaine treatment field, failure to reliably replicate findings
regarding predictors of retention indicates that little progress has been made in identifying key
characteristics associated with treatment drop out, precluding the development of more
efficient and effective strategies to enhance retention.
Several plausible explanations can be invoked for the lack of reliable findings in this area of
research. First, the majority of studies examining retention have tested a large number of
variables without benefit of theoretical models defined a priori, nor even a rationale for
selecting various predictors. Researchers are rejecting this type of search for simple, random
predictors of drop-out (e.g., Harris, 1998). Further, in order to develop a systematic and
coherent literature, investigators need to move beyond research on correlates of attrition and
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begin to propose and test theoretical models with hypothesized causal mechanisms and clearer
implications for preventing attrition, rather than rely on completely data-driven systems which
maximize the likelihood of chance findings (Streiner, 1994, Henderson and Denison, 1989).
At minimum, researchers should select dynamic variables (e.g., motivation, mood) that may
provide implications for treatment development and which may be influenced by intervention,
rather than static, “tombstone” variables (e.g., race). For example, Moeller and colleagues
(2001) specifically investigated the impact of impulsivity on both cocaine use and retention
and found it to be a significant predictor, suggesting that cocaine treatment may benefit from
including components targeting impulsivity. McKay et al. (2000) similarly investigated the
prognostic significance of antisocial personality disorder (ASPD) in cocaine patients, which
led to implications for treatment based on outcomes related to this diagnosis. Once potentially
important constructs such as impulsivity and ASPD are identified, more complex models
estimating the relative contribution for each and potential interactions with other variables can
be developed and tested. Joe and colleagues (1999) provide an excellent example of testing
complex models in their study examining retention, as defined by treatment process
components (session attributes and therapeutic involvement), within the context of patient
factors (e.g., motivation). Without theoretical models, the extremely large number of possible
variable interactions cannot be narrowed, as it is currently not technologically possible to
identify and test all complex interactions of potentially important variables. Thus, we are left
with simplistic models which are not intuitively sufficient to explain a complex human behavior
such as treatment retention. Although opposing arguments can be made, proposing theoretical
models that can be subjected to falsification has been the foundation of deductively rigorous
science.
The failure to reproduce cocaine retention predictor findings across studies and samples may
also be attributed to the lack of specification of important contextual factors, including
therapist, treatment program, study protocol, and sample characteristics (e.g., inclusion,
exclusion criteria). Even seemingly insignificant factors such as staff turnover, program
location, and clinic rules/atmosphere (e.g., relaxed vs. strict observance of clinic rules) may
account for more variance in retention than one might expect (Harris, 1998). Improvements in
client retention may be possible with fairly minor modifications in such factors, e.g., use of a
structured induction to clarify expectations and reduce anxiety, cultural sensitivity training,
and monetary incentives for continuing clients (Zweben and Li, 1981, Walitzer et al., 1999,
Petry, 2000). Thus, contextual factors that may significantly influence retention in treatment
need to be clearly identified in all studies of treatment retention.
Statistical methods used to identify significant predictor variables in cocaine treatment
retention outcomes are also variable across studies. These methods all have associated
advantages and disadvantages and inherently rely on the nature of the dependent variable
selected to measure retention or attrition, also inconsistently chosen across studies. For
example, logistic regression analyses are often used when retention is defined dichotomously
(e.g., treatment completer vs. non-completer). Results from these analyses are easy to interpret,
however, information is lost by collapsing retention data to one binary category. Linear or Cox
regression procedures are typically employed with continuous measures of retention (e.g.,
number of sessions attended). These methods use more of the available data, however
interpretability is often sacrificed. Regardless, differing measures assessed cross-sectionally
using differing statistical analyses of retention are likely to result in the inconsistent
identification of important variables. The consistent use of more sophisticated statistical
methods, such as the longitudinal modeling of complex relationships among patient
characteristics, process variables, and change over time (e.g., Joe et al., 1999) may assist in the
development of reliably reproducible models for understanding retention in treatment.
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Equally if not more problematic are the commonly used automated variable selection (AVS)
methods. Several potential problems with the use of these selection methods have been
identified: (1) R² values are often biased high; (2) estimated standard errors are often biased
low; and (3) results are dependent upon the correlation between the predictor variables. As a
result, AVS methods increase the likelihood of finding chance associations in a sample when
the true association in the population is actually weaker. In addition, the usual test statistics on
which these methods are based were intended for testing hypotheses established a priori and
not post-hoc (Streiner, 1994, Steyerberg et al., 1999, Austin and Tu, 2004, Steyerberg et al.,
2001).
Small sample sizes also pose a challenge for cocaine treatment retention studies and may lead
to discrepant prediction models. Harrell et al (1984, in Altman and Royston, 2000) suggest
that for regression modeling the EPV (events per variable) should be at least ten times the
number of potential prognostic variables included in the model. Others argue that more
complex rules-of-thumb are needed to estimate minimum sample size as a function of the
number of predictors as well as effect size (Green, 1991). Regardless, with limited outcome
events or observations and a large number of baseline characteristics included, the resulting
regression coefficients for individual variables may not be trustworthy, and may represent
spurious associations (Concato et al, 1993). Results of models having fewer than 10 outcome
events per independent variable are questionable in terms of accuracy, and the usual tests of
statistical significance may be invalid. Therefore, recommended limits on subject to variable
ratios need to be adhered to more stringently. Compounding the problem of small sample size
is the dilemma of missing data. If losses to follow-up are large and possibly related to outcome
events, (i.e., not missing at random), then prognostic estimates may be seriously biased (Kelley
and Maxwell, 2003, Harrell et al., 1985).
Possibly most problematic, however, is the lack of an accepted convention or requirement for
validation of findings prior to publication. Within the substance abuse treatment field, initial
predictor models of retention have rarely been cross-validated on independent samples, and
according to the results of the current study are unlikely to confirm initial findings due to factors
described previously (e.g., contextual differences, reliance on methods which capitalize on
chance variables). Methods to maximize internal validation or accuracy of findings drawn from
the original sample may be a necessary first step to enhance generalizability. At minimum,
retention predictor studies should make use of internal validation procedures such as data
exclusion (random split sample) when sample size permits or resampling techniques (e.g.,
bootstrapping). While in the current paper we used bootstrap resampling to illustrate the
instability of prognostic models identified through AVS, they can be used to validate
empirically derived models, and to achieve less biased parameter estimates and accompanying
standard errors (Schumacher et al., 1997). Ideally, internal validation procedures would be
followed by external validation procedures, i.e. testing the accuracy of the system in another
sample at the same site or at different or multiple geographic sites (by independent
investigators).
Concerns about prognostic modeling discussed here in the context of substance abuse treatment
retention are in general not new, however, due to time constraints and pressures to publish they
are largely ignored. The result is a literature on which no firm conclusions can be drawn, and
more importantly which provides no coherent direction for intervention. Based on identified
weaknesses of the literature, several recommendations can be made for future studies
evaluating factors associated with treatment retention (See Table 5). Similar recommendations
can be applied to prediction studies of other substance abuse treatment outcomes and are not
limited specifically to retention. The recommendations are fairly ambitious and will take a
coordinated effort among substance abuse researchers. Failing to address these issues,
Stotts et al. Page 9
Addict Behav. Author manuscript; available in PMC 2008 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
however, will perpetuate a literature of inconsistent, contradictory, and non-generalizable
findings from which no meaningful conclusions can be drawn.
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Appendix A
23 Published Trials Evaluating Predictors of Treatment Retention/Completion in Cocaine-
Abusing Patients
Author Sitea N
Agosti et al., 1991 Study 60
Means et al., 1989 Clinic 81
Kleinman et al., 1992 Clinic 86
Gainey et al., 1993 Study 110
Agosti et al., 1996 Study 198
Roberts and Nishimoto, 1996 Clinic 369
Alterman et al., 1996 Study 95
Alterman et al., 1997 Study 256b
Gottheil et al., 1997 Study 447
Siqueland et al., 1998 Study 286
McMahon et al., 1999 Clinic 54
Mulvaney et al., 1999 Study 87
Pena et al., 1999 Study 294
Alterman et al., 2000 Study 160
McKay et al., 2000 Study 127
Kampman et al., 2001 Study 128
Moeller et al., 2001 Study 50
Sterling et al., 2001 Clinic 116
Sayre et al., 2002 Study 165
Siqueland et al., 2002 Study 487
Levin et al., 2004 Clinic 135
Milligan et al., 2004 Study 111
Patkar et al., 2004 Clinic 141
a
Note: Site denotes population: Clinic = non-select sample, Study = research sample.
b
Sample size consists of 4 samples combined.
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Figure 1.
Retention curves indicating percentage of the sample remaining by days in treatment for three
cocaine treatment studies.
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Figure 2.
For each study, the number of times each variable was selected as a significant predictor of
retention in 1000 derived models using bootstrap resampling analyses with three automated
variable selection procedures (Forward, Backward, and Stepwise).
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Table 2
Sample Characteristics of Three Studies
 All Study 1 Study 2 Study 3
 N = 266 N= 80 N = 80 N= 106
 
 M/% (SD) M/% (SD) M/% (SD) M/% (SD)
Demographic     
  Age 36.4 (6.4) 35.5 (6.7) 35.3 (7.2) 34.4 (6.7)
  Gender (% female) 23 25 29 25
  Race (% non-white) 66 63 59 63
  Education 12.9 (2) 12.7 (2) 12.4 (1.9) 12.7 (2)
  Married 23 24 21 29
  Employed 41 44 41 53
Drug Use     
  Drug Composite 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.2 (0.1)
  Alcohol Composite 0.2 (0.2) 0.2 (0.2) 0.2 (0.2) 0.1 (0.2)
  Alcohol (Past 30 Days) 10.3 (10.3) 12.1 (10.5) 6.4 (8.9) 12.0 (5.5)
  Years Alcohol 11.6 (8.6) 11.9 (9.1) 12.2 (8.8) 12 (10.2)
  Cocaine (Past 30 Days) 12.7 (9.3) 12.3 (8.4) 12.5 (9.6) 13.1 (9.6)
  Years Cocaine 8 (5.3) 8 (5.3) 8.2 (5.1) 8 (5.4)
  Cocaine Route 78 78 75 81
  Drug Treatments 1 (1.4) 1.3 (2.2) 1.1 (1.8) 1.9 (3.2)
  % Cocaine + at intake 62 74 38 71
  Craving Score 73.2 (22.8) 70.2 (23) 71.3 (25.1) 65.3 (20.4)
  % High Motivation 23 19 35 17
Psychosocial     
  Family Composite 0.2 (0.2) 0.2 (0.2) 0.2 (0.2) 0.2 (0.3)
  Psychiatric Composite 0.1 (0.1) 0.1 (0.2) 0.1 (0.2) 0.2 (0.2)
  Employment Composite 0.5 (0.3) 0.5 (0.3) 0.5 (0.3) 0.4 (0.3)
  BDI Score 11.4 (5.6) 11.6 (5.8) 10.1 (5.4) 12.1 (5.5)
Legal     
  Legal Composite 0.2 (0.4) 0.2 (0.4) 0.2 (0.4) 0.4 (0.5)
  #of Convictions 25.5 (38.9) 15.1 (31.4) 14.7 (31.1) 1.7 (2.7)
  % Probation 11 15 10 25
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Table 4
Logistic Regression Analyses for Predictors of Retention Using, Backward, Forward, and Stepwise Retention
Procedures
 Study 1
 
Variable Forward Backward Stepwise
Age χ²(1) = 5.27, p = 0.022 χ²(1) = 5.77, p = 0.016 χ²(1) = 2.86, p = 0.091
Cocaine Use χ²(1) = 3.11, p = 0.078 χ²(1) = 3.87, p = 0.049 –
Sex – χ²(1) = 2.71, p = 0.1 –
ASI Family χ²(1) = 2.76, p = 0.097 – –
    
 Study 2
 
Variable Forward Backward Stepwise
Education χ²(1) = 4.29, p = 0.038 χ²(1) = 4.77, p = 0.029 χ²(1) = 2.86, p = 0.091
    
 Study 3
 
Variable Forward Backward Stepwise
Cocaine Use – χ²(1) = 5.27, p = 0.022 –
Intake Urine – χ²(1) = 3.17, p = 0.075 –
ASI –  –
Psychiatric  χ²(1) = 5.27, p = 0.022  
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Table 5
Recommendations for Improving the Quality of Findings in Prognostic Treatment Retention Studies.
Recommendations
▪ Prospectively develop theoretical models of retention/attrition using dynamic variables
  
▪ Develop conventions for specifying categories of key contextual factors that may impact attrition (e.g., precise characterization of subjects,
procedures, treatment program)
  
▪ Specify conventions for statistical methods and for measurement of retention/attrition to promote consistency across studies
  
▪ Specify minimum sample size and missing data requirements
  
▪ Validate findings prior to publication using split-sample or re-sampling methods
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